Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin Safety and Efficacy in Type 2 Diabetes
NCT01204294Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Sep 2010; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01204294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204294.